Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells

Journal of Orthopaedic Research

Volumn 25, Issue 7, 2007, Pages 964-971

  Guo, Yi ^a   Zi, Xiaolin ^b   Koontz, Zach ^a   Kim, Alison ^a   Xie, Jun ^a   Gorlick, Richard ^c   Holcombe, Randall F ^b   Hoang, Bang H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cadherin; Low density lipoprotein receptor related protein 5; Metastasis; Osteosarcoma; Wnt signaling

Indexed keywords

CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 8; FIBRONECTIN; GELATINASE A; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; SCATTER FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; WNT PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESENCHYME CELL; METASTASIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

BONE NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL CELLS; GENE SILENCING; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MESODERM; METALLOPROTEASES; OSTEOBLASTS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS;

EID: 34447279476     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20356     Document Type: Article

References (29)

1. He TC, Sparks AB, Rago C, et al. 1998. Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
2. Tetsu O, McCormick F. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
3. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. 1999. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891.
4. Hoang BH, Kubo T, Healey JH, et al. 2004. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106-111.
5. Hoang BH, Kubo T, Healey JH, et al. 2004. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64:2734-2739.
6. Mao J, Wang J, Liu B, et al. 2001. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 7:801-809.
7. Gong Y, Slee RB, Fukai N, et al. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
8. Tsai CN, Tsai CL, Tse KP, et al. 2002. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA 99:10084-10089.
9. Seiki M. 2002. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 14:624-632.
10. Coltella N, Manara MC, Cerisano V, et al. 2003. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 17:1162-1164.
11. Kang Y, Massagué J. 2004. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277-279.
12. Furge KA, Zhang YW, Vande Woude GF. 2000. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19:5582-5589.
13. Brinckerhoff CE, Matrisian LM. 2002. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3:207-214.
14. Ferracini R, Di Renzo MF, Scotlandi K, et al. 1995. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10:739-749.
15. Rong S, Jeffers M, Resau JH, et al. 1993. Met expression and sarcoma tumorigenicity. Cancer Res 53:5355-5360.
16. Kamei T, Matozaki T, Sakisaka T, et al. 1999. Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells - regulation by Rho, Rae and Rab small G proteins. Oncogene 18:6776-6784.
17. Kimura T, Sakisaka T, Baba T, et al. 2006. Involvement of the Ras-Ras-activated Rab5 guanine nucleotide exchange factor RIN2-Rab5 pathway in the HGF-induced endocytosis of E-cadherin. J Biol Chem 281(15):10598-10609.
18. Hazan RB, Qiao R, Keren R, et al. 2004. Cadherin switch in tumor progression. Ann N Y Acad Sci 1014: 155-163.
19. Savagner P. 2001. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23:912-923.
20. Yang J, Mani SA, Donaher JL, et al. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939.
21. Man TK, Chintagumpala M, Visvanathan N, et al. 2005. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65:8142-8150.
22. Howe LR, Watanabe O, Leonard J, et al. 2003. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63:1906-1913.
23. Vallin J, Thuret R, Giacomello E, et al. 2001. Cloning and characterization of three Xenopus slug promoters reveal direct regulation by Lef/beta-catenin signaling. J Biol Chem 276:30350-30358.
24. Come C, Arnoux V, Bibeau F, et al. 2004. Roles of the transcription factors snail and slug during mammary morphogenesis and breast carcinoma progression. J Mammary Gland Biol Neoplasia 9:183-193.
25. Sarrio D, Perez-Mies B, Hardisson D, et al. 2004. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23:3272-3283.
26. Nelson AR, Fingleton B, Rothenberg ML, et al. 2000. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135-1149.
27. Uchibori M, Nishida Y, Nagasaka T, et al. 2006. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 28:33-42.
28. Takahashi M, Tsunoda T, Seiki M, et al. 2002. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/ Tcf4 complex in human colorectal cancers. Oncogene 21:5861-5867.
29. Zi X, Guo Y, Simoneau AR, et al. 2005. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65:9762-9770.